
10 For 10 Virtual Challenge 2025
Take on a challenge with #TeamRetinaUK and run, jog or walk 10 miles in your neighbourhood whilst raising money for our cause.
Search results
Take on a challenge with #TeamRetinaUK and run, jog or walk 10 miles in your neighbourhood whilst raising money for our cause.
Biotechnology company Kiora Pharmaceuticals has been given the go-ahead to start in-human testing of a novel “small molecule” treatment, known as KIO-301, for advanced vision loss in retinitis pigmentosa (RP). The phase 1b clinical trial will take place in Adelaide, Australia, and will begin enrolling participants towards the end of 2022.
In spring 2021, the US company jCyte announced detailed results from their successful phase 2b clinical trial of jCell, a stem cell-based treatment for RP.
An American living with Leber congenital amaurosis 10 (LCA10) has become the first clinical trial participant in the world to receive a CRISPR gene editing treatment in vivo (inside the body).
A recording of the 46th Retina UK Annual Conference on 24 June 2023. The Conference was held at the University of Westminster, Marylebone Campus in London and online.
Biotechnology company ProQR has announced that two of its RNA therapy development programmes for inherited sight loss are being acquired by Laboratoires Théa, a company specialising in eye care products.
Nanoscope Therapeutics has announced positive results from their two year randomised controlled phase 2b optogenetic therapy trial for late-stage retinitis pigmentosa (RP).
SalioGen Developing Novel Gene Insertion Therapy for Stargardt disease.
During Loneliness Awareness Week, we're hosting a special webinar to address the challenges faced by individuals with sight loss when it comes to travel and mobility.
During Loneliness Awareness Week, we're hosting a special webinar to address the challenges faced by individuals with sight loss when it comes to travel and mobility.